{"id":55518,"date":"2023-04-04T21:04:14","date_gmt":"2023-04-04T19:04:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/"},"modified":"2023-04-04T21:04:14","modified_gmt":"2023-04-04T19:04:14","slug":"c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/","title":{"rendered":"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023"},"content":{"rendered":"
\n

\nPrecivityAD2\u2122 blood test matches up in amyloid detection to CSF testing and amyloid PET in real-world study of patients with cognitive impairment presenting to primary care<\/i><\/p>\n

\nPrecivity-related blood biomarkers have high accuracy in the cognitively unimpaired population<\/i><\/p>\n

ST. LOUIS–(BUSINESS WIRE)–#Alzheimers<\/a>—C2<\/sub>N Diagnostics<\/a>, a leader in advanced brain health diagnostics, announced the presentation of two research studies at the AD\/PD\u2122 2023 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and related neurological disorders that bolster the role of the Precivity-related blood biomarkers (BBM) to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer\u2019s disease (AD). These findings underscore the ability of the Precivity-related BBM to help clinicians with the diagnosis of AD in cognitively impaired patients as well as risk prediction in unimpaired individuals.<\/p>\n

<\/a><\/p>\n

\nPrecivityAD2 blood test shows robust accuracy in real-world study<\/i><\/b><\/p>\n

\nDr. Sebastian Palmqvist and Dr. Oskar Hansson, neurologists with Sk\u00e5ne University Hospital and Lund University in Sweden, used the PrecivityAD2 blood test<\/a> (Research Use Only) that relies on precise mass spectrometry-based measurements of two key plasma proteins (p-tau and amyloid beta) implicated in AD. The blood test reports out plasma p-tau217 Ratio (phospho-Tau217 \/ non-phospho-tau217) and plasma A\u03b242\/40 Ratio measures as well as the Amyloid Probability Score 2 (APS2) derived from a pre-established regression model based on those ratio measures. The APS2 results determine whether a patient is positive or negative for brain amyloid plaques based on a binary cutoff value.<\/p>\n

\nThe study included 307 patients (average age of 76 years old) with symptoms of cognitive impairment evaluated within primary care sites in Sweden. All patients received the PrecivityAD2 blood test as well as cerebrospinal fluid (CSF) analysis or an amyloid positron emission tomography (PET) scan. The Precivity-related BBM showed robust discrimination between amyloid positive and amyloid negative patients using CSF or PET biomarkers as the reference tests. In particular, the AUC of 0.91 (95% CI 0.88-0.94) for p-tau217 Ratio and AUC of 0.94 (95% CI 0.92-0.97) for the APS2 result were noted. Furthermore, the investigators\u2019 work showed that primary care physicians (PCPs) without use of the blood test diagnosed only 60% of symptomatic AD correctly, leading to overdiagnosis in 23% and underdiagnosis in 17% of patients.<\/p>\n

\nDr. Palmqvist says, \u201cThe primary care physicians\u2019 diagnosis certainty with standard of care only was low, which highlights that they are completely aware that currently available diagnostic tools in primary care are not adequate. The results we\u2019ve seen so far indicate that this can radically change with a blood test for AD. The blood biomarkers showed robust clinical validity and accuracy among patients with comorbidities known to interfere with the performance of plasma. The PrecivityAD2 data represent the highest correlation data I\u2019ve seen for a blood test against corresponding CSF biomarkers.\u201d<\/p>\n

\nPrecivity-related BBM accurately identify amyloid pathology and predict clinical decline in cognitively unimpaired individuals<\/b><\/p>\n

\nIn a separate study, Karly Cody, a Ph.D. candidate at the University of Wisconsin-Madison Alzheimer\u2019s Disease Research Center, found that in a cognitively unimpaired population of 281 individuals, the PrecivityAD2 blood test with the APS2 score had the highest diagnostic accuracy (AUC~96%) for detecting brain amyloid among other BBM studied alone or in combination.<\/p>\n

\nAs an extension of this study, 291 cognitively unimpaired individuals (average age 59) received blood tests and longitudinal cognitive follow-up (mean 8.2 years) to examine the associations of plasma biomarkers with cognitive status over time. When compared against the other individual biomarkers, an elevated value for the p-tau217 ratio (an integral component of the PrecivityAD2 blood test) was the best biomarker for predicting cognitive decline.<\/p>\n

\n\u201c<\/b>We congratulate our collaborators from Sk\u00e5ne University Hospital, Lund University and University of Wisconsin for their outstanding work to further validate C2<\/sub>N\u2019s blood tests in a variety of important clinical applications. These research findings add to the quality and number of Precivity-related biomarker measures we have reported through peer-reviewed publications, which now stands at approximately 10,000,\u201d says Dr. Joel Braunstein, CEO of C2<\/sub>N Diagnostics. \u201cBoth studies reinforce the perspective of the 2022 Clinical Trials On Alzheimer’s Disease Task Force report on the characteristics of an ideal blood biomarker. This means blood biomarkers with prospectively defined endpoints, validation across multiple different independent cohorts, suitability for use in primary care, and the ability to help with both diagnosis and risk prediction. In particular, Dr. Palmqvist\u2019s work highlights that as AD-specific treatments are approved and become widely accessible, the need for detection and accurate diagnosis will be amplified.\u201d<\/p>\n

\nAbout C2<\/sub>N Diagnostics, LLC<\/b><\/p>\n

\nC<\/i>\u2082<\/i>N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation\u00ae. C<\/i>\u2082<\/i>N strives to provide exceptional laboratory services and products in the field of brain health. C<\/i>\u2082<\/i>N\u2019s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer\u2019s Drug Discovery Foundation, BrightFocus Foundation and Alzheimer\u2019s Association. For more information visit <\/i>www.C2<\/a><\/i>N.com<\/i><\/a>.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nCOMPANY CONTACT:
\n
Joni Henderson
\n
Director of Marketing, Outreach and Strategic Growth
\n
C2N Diagnostics
\n
jhenderson@c2n.com<\/a>
571-355-3371<\/p>\n

\nMEDIA CONTACT:
\n
Adam Shapiro
\n
Adam.Shapiro@ASPR.bz<\/a>
202-427-3603<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PrecivityAD2\u2122 blood test matches up in amyloid detection to CSF testing and amyloid PET in real-world study of patients with cognitive impairment presenting to primary care Precivity-related blood biomarkers have high accuracy in the cognitively unimpaired population ST. LOUIS–(BUSINESS WIRE)–#Alzheimers—C2N Diagnostics, a leader in advanced brain health diagnostics, announced the presentation of two research studies … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55518","6":"format-standard","7":"category-industry"},"yoast_head":"\nC2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PrecivityAD2\u2122 blood test matches up in amyloid detection to CSF testing and amyloid PET in real-world study of patients with cognitive impairment presenting to primary care Precivity-related blood biomarkers have high accuracy in the cognitively unimpaired population ST. LOUIS–(BUSINESS WIRE)–#Alzheimers—C2N Diagnostics, a leader in advanced brain health diagnostics, announced the presentation of two research studies ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T19:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230404006012\/en\/1756208\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\\\/PD 2023\",\"datePublished\":\"2023-04-04T19:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/\"},\"wordCount\":928,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404006012\\\/en\\\/1756208\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/\",\"name\":\"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\\\/PD 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404006012\\\/en\\\/1756208\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-04-04T19:04:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404006012\\\/en\\\/1756208\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404006012\\\/en\\\/1756208\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\\\/PD 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/","og_locale":"en_US","og_type":"article","og_title":"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023 - Pharma Trend","og_description":"PrecivityAD2\u2122 blood test matches up in amyloid detection to CSF testing and amyloid PET in real-world study of patients with cognitive impairment presenting to primary care Precivity-related blood biomarkers have high accuracy in the cognitively unimpaired population ST. LOUIS–(BUSINESS WIRE)–#Alzheimers—C2N Diagnostics, a leader in advanced brain health diagnostics, announced the presentation of two research studies ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-04T19:04:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230404006012\/en\/1756208\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023","datePublished":"2023-04-04T19:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/"},"wordCount":928,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230404006012\/en\/1756208\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/","url":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/","name":"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230404006012\/en\/1756208\/21\/logo.jpg","datePublished":"2023-04-04T19:04:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230404006012\/en\/1756208\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230404006012\/en\/1756208\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/c2n-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-ad-pd-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"C2N Diagnostics\u2019 Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer\u2019s Disease in Two Studies Presented at AD\/PD 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55518"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55518\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}